U.S. Senator Tammy Baldwin Leads Bipartisan Amendment to Support Medical Innovations
Amendment funds and advances Department of Energy efforts to produce domestic medical isotopes
WASHINGTON, D.C. – U.S. Senator Tammy Baldwin is leading a bipartisan amendment for inclusion in the Fiscal Year 2019 Energy & Water Development Appropriations Bill that would devote $20 million to continue establishing domestic production of a commonly-used medical isotope needed to conduct health procedures, including cancer and heart screenings.
The amendment, introduced with Senator Rob Portman (R-OH), would support Wisconsin companies like SHINE Medical Technologies in Janesville and NorthStar Medical Radioisotopes in Beloit that are leading the nation in developing key medical innovations.
The amendment would support the Department of Energy’s (DOE) efforts to establish domestic production of the medical isotope Molybdenum-99, or commonly known as Mo-99. Mo-99 helps 50,000 patients a day in the U.S. by providing early detection and enabling treatment of cancer and heart disease.
Mo-99 is not yet made in the United States. Instead, the U.S. imports 100% of supply from foreign nuclear research reactors and production facilities, with the nation’s main supplier being an aging facility in the Netherlands. Mo-99 lasts only three days, so distance from the manufacturer affects both amount and price of supply.
Various groups and entities support domestic production of Mo-99, including the American Cancer Society Cancer Action Network, Lung Cancer Alliance, Medical Imaging Coalition, American College of Radiology, American College of Cardiology, American Society of Nuclear Cardiology, Society of Nuclear Medicine and Molecular Imaging, Cardinal Health, GE Healthcare, and Lantheus Medical Imaging.
Recent Press Releases by U.S. Sen. Tammy Baldwin
Senate Committees Pass Trade Bill for Floor Vote